First- and second-line biomarker utilization in non-small cell lung cancer.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 2552: Real-world analysis of biomarker testing and use of targeted therapies in metastatic non-small cell lung cancer (mNSCLC) in the United States (US)2024
2. 2Matched targeted therapy use after broad genomic profiling in advanced Non-Small cell lung cancer2026
3. 3Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP)2026
4. 4ESMO 2025 and the Future of EGFRm NSCLC Sequencing: First-line Choices that Preserve Subsequent Therapy Eligibility2025
5. 5Biomarker testing and targeted therapy use among patients with non-small cell lung cancer in the United States: An analysis using a physician notes real-world database.2024